

Baxter International Inc.
Key Product Line Sales -- US/International
Period Ending March 31, 2006

(unaudited)

(\$ in millions)	Q1 2006			Q1 2005			% Growth		
	US	International	Total	US	International	Total	US	International	Total
BioScience									
Recombinants	\$161	\$213	\$374	\$145	\$199	\$344	11%	7%	9%
Plasma Proteins ¹	67	125	192	48	122	170	40%	2%	13%
Antibody Therapy	139	44	183	48	41	89	190%	7%	106%
BioSurgery ²	39	30	69	35	31	66	11%	(3%)	5%
Transfusion Therapies	56	68	124	65	68	133	(14%)	-%	(7%)
Other ³	12	46	58	57	43	100	(79%)	7%	(42%)
Total BioScience	\$474	\$526	\$1,000	\$398	\$504	\$902	19%	4%	11%
Medication Delivery									
IV Therapies ⁴	\$104	\$200	\$304	\$94	\$202	\$296	11%	(1%)	3%
Drug Delivery	125	70	195	139	65	204	(10%)	8%	(4%)
Infusion Systems	124	71	195	155	75	230	(20%)	(5%)	(15%)
Anesthesia	133	79	212	158	73	231	(16%)	8%	(8%)
Other ⁵	5	5	10	6	11	17	(17%)	(55%)	(41%)
Total Medication Delivery	\$491	\$425	\$916	\$552	\$426	\$978	(11%)	-%	(6%)
Renal									
PD Therapy	\$66	\$322	\$388	\$62	\$315	\$377	6%	2%	3%
HD Therapy	28	77	105	32	94	126	(13%)	(18%)	(17%)
Total Renal ⁶	\$94	\$399	\$493	\$94	\$409	\$503	-%	(2%)	(2%)
TOTAL BAXTER	\$1,059	\$1,350	\$2,409	\$1,044	\$1,339	\$2,383	1%	1%	1%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, and certain other plasma-based products. Sales of Tisseel, sales of plasma to third parties, and contract manufacturing revenues were previously reported in Plasma Proteins, and are now reported in other product lines, as detailed below.*

² Includes sales of Tisseel and FloSeal/CoSeal, which were previously reported in Plasma Proteins and Other, respectively.*

³ Principally includes vaccines and sales of plasma to third parties. The sales of plasma to third parties were previously reported in Plasma Proteins. The prior year sales include contract manufacturing revenues.*

⁴ Principally includes intravenous solutions and nutritional products.

⁵ Principally includes other hospital-distributed products.

⁶ Sales of pharmaceutical and certain other products, which were previously reported in Other, are now reported in PD Therapy.*

* Prior year sales data has been reclassified to reflect the above-mentioned changes.